Exagamglogene autotemcel (exa-cel) (Casgevy®) is a gene therapy for treating sickle cell disease in patients 12 years and older with recurrent vaso-occlusive crises and transfustion-dependent beta ...

Gene therapy has always held enormous promise to correct genetic diseases, but turning that potential into treatments has ...

"We have about eight patients that are in the insurance approval process," she said, for gene therapy treatments for beta thalassemia and sickle cell disease. "It's something that we do expect to ...

Editas Medicine reports successful gene editing levels in stem cells, supporting potential treatment for sickle cell disease and beta thalassemia. Editas Medicine announced promising new data on ...

A three-year study by Metropolis Healthcare reveals that 28.4 per cent of nearly 20,000 children screened for ...

A new study reveals that over one in four Indian children under 12 carry inherited blood disorders. The findings highlight ...